Search
Tony Keating says the study reveals many issues in the quality of cough recordings, and is not what the company expected.

ResApp crashes on study results

Shares in medical tech company ResApp Health plummeted 77 per cent today on disappointing results of a clinical study on its ResAppDx technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Source: Morningstar

Total Shareholder Return as at 30/08/19

1 year TSR5 year TSR
250thProteomics International Laboratories15%
274thResApp Health10%98%
312thAlterra2%10%
602ndOBJ-38%-31%
736 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

05/10/17
$65k Bought
16/12/16
$49k Bought
16/12/16
$49k Other
Total value as at the date of the transaction
Source: Morningstar

Revenue

103rd↑Alterra$2.9m
104th↑Ephraim Resources$2.9m
105th↑ResApp Health$2.7m
106th↑OBJ$2.7m
107th↑Proteomics International Laboratories$2.7m
197 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer